Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Pacific Biosciences of California faces steep stock decline and financial challenges. Click here to see why PACB stock is a ...

A research team has identified two novel genetic mechanisms for disease resistance in wheat, offering promising strategies to ...

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly ...

Pacific Biosciences offers advanced long-read sequencing, simplifying genome assembly and providing higher taxonomic resolution in specific research niches. While earnings were a beat, shrinking ...

PacBio PACB recently announced a key distribution agreement with Haorui Gene, a globally recognized leader in blood typing genomics. This strategic partnership grants PacBio access to a wider ...

The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance ...

PacBio (Nasdaq: PACB) and Chulalongkorn University, announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51 ...

Pacific Biosciences PACB has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...